Details checkedClinical trial listing onlyCheckedregistry

Chang Gung hydroxychloroquine adjunct SSNHL study

Also known as: Hydroxychloroquine, Steroid, Prednisolone, Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss, CPRPG8P0011, NCT06467526

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Active

Target Gene

—

Route / Mode

Oral hydroxychloroquine plus steroid care

Confidence

80%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Taiwan

Population

adult, sudden, sensorineural, tinnitus, combination-study

Trial IDs

Mechanism

Oral hydroxychloroquine 400 mg/day for 60 days added to oral prednisolone steroid care, compared with steroid care alone, for sudden sensorineural hearing loss recovery.

Indications

Hearing Loss Sudden Hearing Loss Sensorineural Hearing Loss Tinnitus

Notes

Collapsed the generated hydroxychloroquine and steroid rows into one Chang Gung-led Phase 2 SSNHL adjunct-treatment study. The registry lists the study as not yet recruiting, so this is a verified study-level record rather than an active company program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT06467526, CPRPG8P0011

Open

Key Events

2024-06-21

Chang Gung hydroxychloroquine SSNHL study first posted

Clinical Trials (1)

NCT06467526

Data Checks